Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BioMS (TSE:MS) said its MBP8298 peptide did not meet the primary endpoint of stabilizing progression of multiple sclerosis (MS) as measured
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury